Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents

Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents

P-glycoprotein (P-gp) inhibition has been studied to overcome multidrug resistance in cancer chemotherapy but failed in clinical trials due to low/toxic effects. Recently, a dual modulation of transporters and natural derivatives have been examined to surmount this limitation. We examined breast can...

Full description

Bibliographic Details
Main Authors: Jaeok Lee, Jiyeon Kang, Na-Yun Kwon, Aneesh Sivaraman, Ravi Naik, So-Young Jin, A. Reum Oh, Jae-Ho Shin, Younghwa Na, Kyeong Lee, Hwa-Jeong Lee
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceutics
Subjects:
P-gp and BCRP dual inhibition
topotecan
excipient
oral bioavailability
pharmacokinetics
tumor growth
Online Access:https://www.mdpi.com/1999-4923/13/4/559

Internet

https://www.mdpi.com/1999-4923/13/4/559

Similar Items